Economic burden of inpatients infected with Klebsiella pneumoniae carbapenemase

10Citations
Citations of this article
64Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVE: To estimate the direct medical costs of drug therapy of Klebsiella pneumoniae carbapenemase (KPC) infection patients in hospital-based context. METHODS: A cost-of-illness study conducted with a prospective cohort design with hospitalized adults infected by KPC. Data collection was performed using an instrument composed of sociodemographic data, clinical and prescription medication. Estimates of the direct costs associated to each treatment were derived from the payer's perspective, in the case of federal public hospitals from Brazil, and included only drug costs. These costs were based on the average price available at the Brazilian Price Database Health. No discount rate was used for the cost of drugs. The costs are calculate in American Dollar (US$). RESULTS: A total of 120 inpatients participated of this study. The total drug cost of these inpatients was US$ 367,680.85. The systemic antimicrobial group was responsible for 59.5% of total costs. The direct drug cost per patients infected by KPC was conservatively estimated at nearly US$ 4,100.00, and about of 60% of costs occurred during the period of infection. CONCLUSION: The findings of our study indicate a thoughtful economic hazard posed by KPC that all healthcare sectors have to face. The increasing worldwide incidence of these bacteria represents a growing burden that most health systems are unable to deal with. There is an imperative need to develop protocols and new antimicrobials to treatment of KPC, aiming to rearrange resources to increase the effectiveness of healthcare services.

Cited by Powered by Scopus

General Overview of Klebsiella pneumonia: Epidemiology and the Role of Siderophores in Its Pathogenicity

39Citations
N/AReaders
Get full text

Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant Klebsiella pneumoniae in vitro

28Citations
N/AReaders
Get full text

Vaccine value profile for Klebsiella pneumoniae

12Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Santos, W. M. D., & Secoli, S. R. (2019). Economic burden of inpatients infected with Klebsiella pneumoniae carbapenemase. Einstein (Sao Paulo, Brazil), 17(4), eGS4444. https://doi.org/10.31744/einstein_journal/2019GS4444

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 18

58%

Researcher 9

29%

Professor / Associate Prof. 3

10%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 8

36%

Immunology and Microbiology 7

32%

Biochemistry, Genetics and Molecular Bi... 4

18%

Pharmacology, Toxicology and Pharmaceut... 3

14%

Save time finding and organizing research with Mendeley

Sign up for free